Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

Shares of NASDAQ:TRVN opened at $1.68 on Tuesday. Trevena has a 52-week low of $1.13 and a 52-week high of $19.23. The company has a market capitalization of $1.44 million, a PE ratio of -0.04 and a beta of 1.08. The company has a fifty day moving average of $2.86 and a 200-day moving average of $5.45.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. On average, equities analysts forecast that Trevena will post -23.04 EPS for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.